221 related articles for article (PubMed ID: 23807188)
1. Intravitreal anti-vascular endothelial growth factor for retinal angiomatous proliferation in treatment-naive eyes: long-term functional and anatomical results using a modified PrONTO-style regimen.
Gharbiya M; Parisi F; Cruciani F; Bozzoni-Pantaleoni F; Pranno F; Abdolrahimzadeh S
Retina; 2014 Feb; 34(2):298-305. PubMed ID: 23807188
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results.
Gharbiya M; Allievi F; Recupero V; Martini D; Mazzeo L; Gabrieli CB
Retina; 2009 Jun; 29(6):740-9. PubMed ID: 19516116
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography.
Inoue M; Arakawa A; Yamane S; Kadonosono K
Br J Ophthalmol; 2014 Jul; 98(7):956-60. PubMed ID: 24599418
[TBL] [Abstract][Full Text] [Related]
4. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation.
Parodi MB; Iacono P; Menchini F; Sheth S; Polini G; Pittino R; Bandello F
Acta Ophthalmol; 2013 May; 91(3):267-73. PubMed ID: 21951313
[TBL] [Abstract][Full Text] [Related]
6. RETINAL PIGMENT EPITHELIAL TEAR AND ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION: Clinical Course and Long-Term Prognosis.
Heimes B; Farecki ML; Bartels S; Barrelmann A; Gutfleisch M; Spital G; Lommatzsch A; Pauleikhoff D
Retina; 2016 May; 36(5):868-74. PubMed ID: 26655607
[TBL] [Abstract][Full Text] [Related]
7. Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.
Cho HJ; Lee TG; Han SY; Kim HS; Kim JH; Han JI; Lew YJ; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):23-30. PubMed ID: 25825231
[TBL] [Abstract][Full Text] [Related]
8. Fibrovascular pigment epithelial detachment is a risk factor for long-term visual decay in neovascular age-related macular degeneretion.
Hoerster R; Muether PS; Sitnilska V; Kirchhof B; Fauser S
Retina; 2014 Sep; 34(9):1767-73. PubMed ID: 24936942
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up for type 1 (subretinal pigment epithelium) neovascularization using a modified "treat and extend" dosing regimen of intravitreal antivascular endothelial growth factor therapy.
Engelbert M; Zweifel SA; Freund KB
Retina; 2010 Oct; 30(9):1368-75. PubMed ID: 20517175
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal anti-VEGF therapy for vascularized pigment epithelium detachment in age-related macular degeneration.
Giansanti F; Bacherini D; Giacomelli G; Virgili G; Finocchio L; Fiore T; Vannozzi L; Menchini U
Eur J Ophthalmol; 2014; 24(3):402-8. PubMed ID: 24242217
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
Treumer F; Roider J; Hillenkamp J
Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
[TBL] [Abstract][Full Text] [Related]
12. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
14. Long-term results of repeated anti-vascular endothelial growth factor therapy in eyes with retinal pigment epithelial tears.
Moreira CA; Arana LA; Zago RJ
Retina; 2013 Feb; 33(2):277-81. PubMed ID: 23023526
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation.
Ghazi NG; Knape RM; Kirk TQ; Tiedeman JS; Conway BP
Retina; 2008 May; 28(5):689-95. PubMed ID: 18463511
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal ranibizumab for macular oedema secondary to retinal vein occlusion: a retrospective study of 34 eyes.
Puche N; Glacet A; Mimoun G; Zourdani A; Coscas G; Soubrane G
Acta Ophthalmol; 2012 Jun; 90(4):357-61. PubMed ID: 20602625
[TBL] [Abstract][Full Text] [Related]
17. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.
Schmidt-Erfurth U; Waldstein SM; Deak GG; Kundi M; Simader C
Ophthalmology; 2015 Apr; 122(4):822-32. PubMed ID: 25578255
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal anti-vascular endothelial growth factor for submacular hemorrhage from choroidal neovascularization.
Kim JH; Chang YS; Kim JW; Kim CG; Yoo SJ; Cho HJ
Ophthalmology; 2014 Apr; 121(4):926-35. PubMed ID: 24342019
[TBL] [Abstract][Full Text] [Related]
19. Comparison of intravitreal triamcinolone acetonide with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation.
Saito M; Shiragami C; Shiraga F; Kano M; Iida T
Am J Ophthalmol; 2010 Mar; 149(3):472-81.e1. PubMed ID: 20053392
[TBL] [Abstract][Full Text] [Related]
20. Ranibizumab in retinal angiomatous proliferation (RAP): influence of RAP stage on visual outcome.
Reche-Frutos J; Calvo-Gonzalez C; Pérez-Trigo S; Fernandez-Perez C; Donate-Lopez J; Garcia-Feijoo J
Eur J Ophthalmol; 2011; 21(6):783-8. PubMed ID: 21484755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
